In addition, although there is evidence that using [TIMP‐2] × [IGFBP7] in combination with routine testing, including SCr and urine volume, within 12 h of patient evaluation in the general surgical ICU helps predict the progression of AKI, there is little substantive evidence that its use improves clinically important patient outcomes [71]. The gene discussed is IGFBP7; the disease is acute kidney injury.